{
  "first_published_at": "2008-01-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084708", 
  "title": "Bivalirudin: risks associated with incorrect dose", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 306, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Bivalirudin: risks associated with incorrect dose</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Use the approved dose regimen for bivalirudin in percutaneous coronary intervention<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Bivalirudin (Angiox&#9660;) is a direct thrombin inhibitor that is approved for use as an anticoagulant in patients who are undergoing percutaneous coronary intervention (PCI). The approved dose for this indication is a 0&middot;75-mg/kg bolus followed immediately by a 1&middot;75-mg/kg/h infusion for the duration of the intervention.</p><p>About 35% of patients entered into a European registry study (enrolled from various countries, but not the UK) received a single bolus or double bolus of bivalirudin without the required maintenance infusion. Most affected patients were recruited in Germany. These non-approved regimens resulted in substantial underdosing and were associated with an increased incidence of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and urgent revascularisation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The approved dosing regimen for bivalirudin should be used in PCI. Use of a maintenance infusion after an initial bolus is necessary to ensure adequate anticoagulation during PCI.</li>\r\n\t\t\t</ul></div><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032914\" target=\"_blank\">Letter sent to healthcare professionals in October 2007</a></p><p><a href=\"http://www.medicines.org.uk/EMC/medicine/16741/SPC/Angiox+250mg+powder+for+concentrate+for+solution+for+injection+or+infusion/\" target=\"_blank\">Summary of Product Characteristics for Angiox&#9660;</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Jan 2008; Vol 1 Issue 6: 7</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Bivalirudin (Angiox&#9660;) is a direct thrombin inhibitor that is approved for use as an anticoagulant in patients who are undergoing percutaneous coronary intervention (PCI). The approved dose for this indication is a 0&#183;75-mg/kg bolus followed immediately by a 1&#183;75-mg/kg/h infusion for the duration of the intervention.</p><p>About 35% of patients entered into a European registry study (enrolled from various countries, but not the UK) received a single bolus or double bolus of bivalirudin without the required maintenance infusion. Most affected patients were recruited in Germany. These non-approved regimens resulted in substantial underdosing and were associated with an increased incidence of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and urgent revascularisation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The approved dosing regimen for bivalirudin should be used in PCI. Use of a maintenance infusion after an initial bolus is necessary to ensure adequate anticoagulation during PCI.</li>\r\n\t\t\t</ul></div><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032914\" target=\"_blank\">Letter sent to healthcare professionals in October 2007</a></p><p><a href=\"http://www.medicines.org.uk/EMC/medicine/16741/SPC/Angiox+250mg+powder+for+concentrate+for+solution+for+injection+or+infusion/\" target=\"_blank\">Summary of Product Characteristics for Angiox&#9660;</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Jan 2008; Vol 1 Issue 6: 7</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-01-01", 
  "date_last_modified": "2010-08-27", 
  "_assets": [], 
  "_item_id": 306, 
  "summary": "Use the approved dose regimen for bivalirudin in percutaneous coronary intervention", 
  "body": "Article date: January 2008\n\nBivalirudin (Angiox▼) is a direct thrombin inhibitor that is approved for use as an anticoagulant in patients who are undergoing percutaneous coronary intervention (PCI). The approved dose for this indication is a 0·75-mg/kg bolus followed immediately by a 1·75-mg/kg/h infusion for the duration of the intervention.\n\nAbout 35% of patients entered into a European registry study (enrolled from various countries, but not the UK) received a single bolus or double bolus of bivalirudin without the required maintenance infusion. Most affected patients were recruited in Germany. These non-approved regimens resulted in substantial underdosing and were associated with an increased incidence of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and urgent revascularisation.\n\nAdvice for healthcare professionals:  \n  \n  * The approved dosing regimen for bivalirudin should be used in PCI. Use of a maintenance infusion after an initial bolus is necessary to ensure adequate anticoagulation during PCI.  \n  \n[Letter sent to healthcare professionals in October 2007](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032914)\n\n[Summary of Product Characteristics for Angiox▼](http://www.medicines.org.uk/EMC/medicine/16741/SPC/Angiox+250mg+powder+for+concentrate+for+solution+for+injection+or+infusion/)\n\n \n\nArticle citation: Drug Safety Update Jan 2008; Vol 1 Issue 6: 7\n"
}